Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL873375 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL29762987 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL11330106 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL30296418 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL6352272 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL867188 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL10840673 | 0.82 | — | — | |
| SCHEMBL12468765 | 0.82 | — | — | |
| SCHEMBL68640 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL48670 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112851563-A | Synthesis process of N-amino-3-azabicyclo [3,3,0] octane hydrochloride | 安徽金鼎医药股份有限公司 | 2021-05-28 | — | — | CN | claimed |
| CN-111303163-B | Compound with JAK kinase inhibitory activity, preparation method, composition and application | 北京鑫开元医药科技有限公司 | 2020-08-11 | — | — | CN | claimed |
| CN-111303163-A | Compound with JAK kinase inhibitory activity, preparation method, composition and application | 北京鑫开元医药科技有限公司 | 2020-06-19 | — | — | CN | claimed |
| EP-2280007-B1 | THE PREPARATION METHOD OF (3S,4S)-3-HEXYL-4-((R)-2-HYDROXYTRIDECYL)-OXETAN-2-ONE AND THE PRODUCT OF THAT METHOD | CHONGQING ZHIEN PHARMACEUTICAL CO LTD (CN) | 2015-04-29 | — | — | EP | claimed |
| US-8431726-B2 | Preparation method of (3S,4S)-3-hexyl-4-((R)-2-hydroxytridecyl)-oxetan-2-one and the product of that method | Chongqing Zhien Pharmaceutical Co., Ltd. | 2013-04-30 | — | — | US | claimed |
| US-20110046400-A1 | PREPARATION METHOD OF (3S,4S)-3-HEXYL-4-((R)-2-HYDROXYTRIDECYL)-OXETAN-2-0NE AND THE PRODUCT OF THAT METHOD | Chongqing Zhien Pharmaceutical Co., Ltd. (CN) | 2011-02-24 | — | — | US | claimed |
| EP-2280007-A1 | THE PREPARATION METHOD OF (3S,4S)-3-HEXYL-4-((R)-2-HYDROXYTRIDECYL)-OXETAN-2-ONE AND THE PRODUCT OF THAT METHOD | Chongqing Zhien Pharmaceutical Co., Ltd. (CN) | 2011-02-02 | — | — | EP | claimed |
| CN-118027134-A | Synthesis method of veratramine | 四川大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-116239643-A | Engliflozin intermediate compound | 山东新时代药业有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-110698467-B | Synthesis method of englitjing | 黄冈鲁班药业股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11649244-B2 | Method for synthesizing diaza-bridged compound and a diaza-bridged compound | LinkChem Co., Ltd., Shanghai (CN) | 2023-05-16 | — | — | US | disclosed |
| CN-115650826-A | Preparation method of novel dapagliflozin intermediate | 江苏阿尔法药业股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-113999239-B | Method for synthesizing diaza-bridge compound | 上海凌富药物研究有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-9604914-B2 | Process for preparing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| EP-2280007-B1 | THE PREPARATION METHOD OF (3S,4S)-3-HEXYL-4-((R)-2-HYDROXYTRIDECYL)-OXETAN-2-ONE AND THE PRODUCT OF THAT METHOD | CHONGQING ZHIEN PHARMACEUTICAL CO LTD (CN) | 2015-04-29 | — | — | EP | disclosed |
| EP-2809645-A1 | PROCESS FOR PREPARING N-(4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXY)-ACETIMIDIC ACID ETHYL ESTER | Novartis AG (CH) | 2014-12-10 | — | — | EP | disclosed |
| WO-2013113915-A1 | PROCESS FOR PREPARING N-(4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXY)-ACETIMIDIC ACID ETHYL ESTER | NOVARTIS AG (CH) | 2013-08-08 | — | — | WO | disclosed |
| US-8431726-B2 | Preparation method of (3S,4S)-3-hexyl-4-((R)-2-hydroxytridecyl)-oxetan-2-one and the product of that method | Chongqing Zhien Pharmaceutical Co., Ltd. | 2013-04-30 | — | — | US | disclosed |
| US-20110046400-A1 | PREPARATION METHOD OF (3S,4S)-3-HEXYL-4-((R)-2-HYDROXYTRIDECYL)-OXETAN-2-0NE AND THE PRODUCT OF THAT METHOD | Chongqing Zhien Pharmaceutical Co., Ltd. (CN) | 2011-02-24 | — | — | US | disclosed |
| EP-2280007-A1 | THE PREPARATION METHOD OF (3S,4S)-3-HEXYL-4-((R)-2-HYDROXYTRIDECYL)-OXETAN-2-ONE AND THE PRODUCT OF THAT METHOD | Chongqing Zhien Pharmaceutical Co., Ltd. (CN) | 2011-02-02 | — | — | EP | disclosed |